• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Autism - Pipeline Review, H2 2011 - Product Image

Autism - Pipeline Review, H2 2011

  • Published: September 2011
  • 79 pages
  • Global Markets Direct

Autism - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Autism - Pipeline Review, H2 2011', provides an overview of the Autism therapeutic pipeline. This report provides information on the therapeutic development for Autism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Autism. 'Autism - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Autism.
- A review of the Autism products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Autism Overview
Therapeutics Development
An Overview of Pipeline Products for Autism
Autism Therapeutics under Development by Companies
Autism Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Autism Therapeutics - Products under Development by Companies
Autism Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Autism Therapeutics Development
Neuropharm Group Plc
Shenzhen Beike Biotechnology Co., Ltd.
Seaside Therapeutics
Snowdon Inc.
Curemark, LLC
Cellceutix Pharmaceuticals, Inc.
Autism - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CM-AT - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STX209 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Celexa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Mecamylamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trichuris Suis Ova - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KM-391 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
N-Acetylcysteine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zyprexa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fluoxetine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Olanzapine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ziprasidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Succimer - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine + Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bumetanide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tpoiramate + Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pentoxifylline + Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Risperidone + Celecoxib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Buspirone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sertraline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aripiprazole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aripiprazole + D-cycloserine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Donepezil HCl - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-Cycloserine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Abilify - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxytocin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Risperidone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Program For Neurological Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Cord Blood Mononuclear Cells + Human Umbilical Cord Mesenchymal Stem Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Memantine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Cord Blood Mononuclear Cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
STX110 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autism Therapeutics – Drug Profile Updates
Autism Therapeutics - Discontinued Products
Autism - Featured News
Jul 08, 2011: Seaside Presents Phase IIa Data On STX209 In Autism Spectrum Disorders At 42nd Autism Society National Conference
Jun 21, 2011: Seaside Therapeutics Initiates Phase IIb Study Of STX209 In Autism Spectrum Disorders
Mar 21, 2011: Curemark Completes Enrollment Of Phase III Trials For CM-AT In Autism
Oct 27, 2010: Curemark Adds Two Autism Trial Sites In California
Sep 09, 2010: Seaside Reports Positive Data From Phase II Study Of STX209 In Autism Spectrum Disorders
Jun 23, 2010: Cellceutix Autism Research With KM-391 Demonstrates Increase In Serotonin Levels In Three Areas Of Brain
Jun 14, 2010: Cellceutix Corporation Announces Positive Results Of KM-391
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Autism, H2 2011
Products under Development for Autism – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Neuropharm Group Plc, H2 2011
Shenzhen Beike Biotechnology Co., Ltd., H2 2011
Seaside Therapeutics, H2 2011
Snowdon Inc., H2 2011
Curemark, LLC, H2 2011
Cellceutix Pharmaceuticals, Inc., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Autism Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Autism, H2 2011
Products under Development for Autism – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos